Status:

COMPLETED

Quantification of Tenofovir Alafenamide Adherence (QUANTI-TAF)

Lead Sponsor:

University of Colorado, Denver

Collaborating Sponsors:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

HIV/AIDS

Adherence, Medication

Eligibility:

All Genders

18+ years

Brief Summary

This study is being done to evaluate the relationship between adherence to antiretroviral therapy (ART) and HIV drug concentrations in persons living with HIV (PLWH) that are taking tenofovir alafenam...

Detailed Description

PLWH taking or initiating/re-initiating TAF will be recruited for a 16-week study. Upon entering the study, participants will be trained on the use the digital pill to objectively quantify adherence. ...

Eligibility Criteria

Inclusion

  • Females or males with HIV, able to give informed consent and comply with study procedures.
  • Currently on (\> 6 months), or planning to initiate/re-initiate TAF.

Exclusion

  • For females of childbearing age, active pregnancy or any intent to become pregnant
  • Hepatitis C (HCV) infection for which treatment is anticipated within the next 16 weeks after enrollment. Treated HCV with sustained virologic response is allowable if last dose of HCV antivirals was \>12 months prior to enrollment
  • Advanced renal (eGFR \<30 mL/min/1.73m\*\*2) or liver (Child-Pugh B or C) disease
  • History of extensive bowel surgery, gastric bypass, or gastroparesis
  • Concomitant use of any prescription or non-prescription drug known (or with the potential) to significantly influence the PK of TAF (e.g. rifamycins, carbamazepine, phenytoin, St. John's Wort, tipranavir)

Key Trial Info

Start Date :

November 21 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

May 16 2023

Estimated Enrollment :

84 Patients enrolled

Trial Details

Trial ID

NCT04065347

Start Date

November 21 2019

End Date

May 16 2023

Last Update

August 27 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Colorado

Aurora, Colorado, United States, 80045

Quantification of Tenofovir Alafenamide Adherence (QUANTI-TAF) | DecenTrialz